Clinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders
- PMID: 25699085
- PMCID: PMC4332923
- DOI: 10.1186/s12991-015-0042-6
Clinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders
Abstract
Aims: This study aimed to compare the performance of Positive and Negative Syndrome Scale (PANSS) symptom severity criteria established by the Remission in Schizophrenia Working Group (RSWG) with criteria based on Clinical Global Impression (CGI) severity score. The 6-month duration criterion was not taken into consideration.
Methods: A convenience sample of 112 chronic psychotic outpatients was examined. Symptomatic remission was evaluated according to RSWG severity criterion and to a severity criterion indicated by the overall score obtained at CGI-Schizophrenia (CGI-SCH) rating scale (≤3) (CGI-S).
Results: Clinical remission rates of 50% and 49.1%, respectively, were given by RSWG and CGI-S, with a significant level of agreement between the two criteria in identifying remitted and non-remitted cases. Mean scores at CGI-SCH and PANSS scales were significantly higher among remitters, independent of the remission criteria adopted. Measures of cognitive functioning were largely independent of clinical remission evaluated according to both RSWG and CGI-S. When applying RSWG and CGI-S criteria, the rates of overall good functioning yielded by Personal and Social Performance scale (PSP) were 32.1% and 32.7%, respectively, while the mean scores at PSP scale differed significantly between remitted and non-remitted patients, independent of criteria adopted. The proportion of patients judged to be in a state of well-being on Social Well-Being Under Neuroleptics-Short Version scale (SWN-K) were, respectively, 66.1% and 74.5% among remitters according to RSWG and CGI-S; the mean scores at the SWN scale were significantly higher only among remitters according to CGI-S criteria.
Conclusions: CGI severity criteria may represent a valid and user-friendly alternative for use in identifying patients in remission, particularly in routine clinical practice.
Similar articles
-
Assessment of functioning in patients with schizophrenia and schizoaffective disorder with the Mini-ICF-APP: a validation study in Italy.Int J Ment Health Syst. 2015 Oct 31;9:37. doi: 10.1186/s13033-015-0030-x. eCollection 2015. Int J Ment Health Syst. 2015. PMID: 26526168 Free PMC article.
-
Is it true remission? A study of remitted patients affected by schizophrenia and schizoaffective disorders.Psychiatry Res. 2013 Dec 30;210(3):739-44. doi: 10.1016/j.psychres.2013.08.022. Epub 2013 Sep 3. Psychiatry Res. 2013. PMID: 24007858
-
Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances.Schizophr Res Cogn. 2014 Dec 8;1(4):187-192. doi: 10.1016/j.scog.2014.11.001. eCollection 2014 Dec. Schizophr Res Cogn. 2014. PMID: 29379752 Free PMC article.
-
Symptom rating scales and outcome in schizophrenia.Br J Psychiatry Suppl. 2007 Aug;50:s7-14. doi: 10.1192/bjp.191.50.s7. Br J Psychiatry Suppl. 2007. PMID: 18019038 Review.
-
Relationships between global assessment of functioning and other rating scales in clinical trials for schizophrenia.Psychiatry Res. 2015 Jun 30;227(2-3):265-9. doi: 10.1016/j.psychres.2015.02.024. Epub 2015 Apr 1. Psychiatry Res. 2015. PMID: 25882098 Review.
Cited by
-
Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis.Front Psychiatry. 2022 Apr 28;13:877867. doi: 10.3389/fpsyt.2022.877867. eCollection 2022. Front Psychiatry. 2022. PMID: 35573364 Free PMC article.
-
A multidisciplinary approach to mental illness: do inflammation, telomere length and microbiota form a loop? A protocol for a cross-sectional study on the complex relationship between inflammation, telomere length, gut microbiota and psychiatric disorders.BMJ Open. 2020 Jan 26;10(1):e032513. doi: 10.1136/bmjopen-2019-032513. BMJ Open. 2020. PMID: 31988227 Free PMC article.
-
Can Non-specific Blood Inflammatory Biomarkers Predict Recovery in Acute Transient Psychotic Disorder? A Prospective Observational Study.Indian J Psychol Med. 2025 Feb 14:02537176251317648. doi: 10.1177/02537176251317648. Online ahead of print. Indian J Psychol Med. 2025. PMID: 39957793 Free PMC article.
-
Converging Evidence Points to BDNF as Biomarker of Depressive Symptoms in Schizophrenia-Spectrum Disorders.Brain Sci. 2022 Dec 4;12(12):1666. doi: 10.3390/brainsci12121666. Brain Sci. 2022. PMID: 36552127 Free PMC article.
-
Cohort profile: demographic and clinical characteristics of the MILESTONE longitudinal cohort of young people approaching the upper age limit of their child mental health care service in Europe.BMJ Open. 2021 Dec 16;11(12):e053373. doi: 10.1136/bmjopen-2021-053373. BMJ Open. 2021. PMID: 34916319 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous